Aton (ALTAO.PA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | - | 1 | 0 | - |
| Operating profit | €m | -1 | -1 | ||||||
| Net profit | €m | -0 | 0 | -1 | -19 | - | -1 | - | - |
| EPS reported | € | -0.00 | -0.00 | ||||||
| Operating cashflow per share | € | 0.00 | 0.00 | ||||||
| Capex per share | € | 0.00 | 0.00 | ||||||
| FCF per share | € | 0.00 | 0.00 | ||||||
| Free cash flow | €m | 0 | 0 | ||||||
| Net debt | €m | 3 | 3 | ||||||
| Book value equity | €m | - | 0 | ||||||
| Book value per share | € | 0.00 | 0.00 | ||||||
| Number of shares | m | 811.22 | 383.15 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 157.86 | 157.86 | ||||||
| P/S LTM | x | 8.84 | 15.22 | ||||||
| P/FCF LTM | x | 41.13 | 102.19 | ||||||
| EV/EBITDA LTM | x | -99.39 | -22.94 | ||||||
| EV/Sales LTM | x | 15.64 | 28.75 | ||||||
| Earnings Yield LTM | % | -16.47% | -8.24% | ||||||
| FCF Yield | % | +2.43% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | -2600.0% | +41.39% | ||||||
| ROIC | % | -14.96% | -14.96% | ||||||
| Operating margin | % | -1.21% | -1.21% | ||||||
| Gross margin | % | +74.28% | +74.28% | ||||||
| FCF/Sales | % | +21.48% | +21.48% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +72.22% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.03 | 0.00 | ||||||
| Net Debt/EBITDA | x | -43.23 | -43.23 | ||||||
| EBIT/Net interest | x | -14.29 | -14.29 | ||||||
| Net debt/market cap | % | +53.25% | +21.43% | ||||||
| Net debt/Equity | x | - | 71.76 | ||||||
| Gross debt/equity | x | - | 133.81 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Based in France, Aton operates as a bioscience enterprise, with its headquarters located in Strasbourg. Established in 1998, the company's extensive operations encompass pharmaceutical research and development, the provision of preclinical and clinical services, and the creation of monoclonal antibodies. Additionally, Aton manufactures laboratory equipment, designs and produces various medical devices—including specialized surgical instruments powered by Stemcis technology—and supplies human tissues.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Based in France, Aton operates as a bioscience enterprise, with its headquarters located in Strasbourg. Established in 1998, the company's extensive operations encompass pharmaceutical research and development, the provision of preclinical and clinical services, and the creation of monoclonal antibodies. Additionally, Aton manufactures laboratory equipment, designs and produces various medical devices—including specialized surgical instruments powered by Stemcis technology—and supplies human tissues.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free